Image credit: shutterstock
US-based Beckman Coulter Diagnostics and Fujirebio, a leader in neurological markers and In Vitro Diagnostic (IVD) manufacturing in Japan, have announced a new partnership combining their respective immunoassay strengths to support therapeutic development, clinical trials, reimbursement, and routine clinical adoption in the field of neurodegenerative diseases.
Currently, Alzheimer's Disease International estimates over 55 million people worldwide are living with dementia and the number of people affected is set to rise to 139 million by 2050.With more than 100 disease modifying drug candidates under development, the pipeline for new therapeutics has never been more robust. The recent approval by the FDA of two monoclonal antibody-based therapeutics is a major milestone in improving Alzheimer's patients' health and slowing down disease progression.
The intersection of the growing prevalence of neurodegenerative disease and advances in disease-modifying therapies for Alzheimer's Disease makes the new Beckman Coulter and Fujirebio partnership evermore critical.
This joint effort relies on Fujirebio's expertise in developing its first-to-market, high-quality neurodegenerative disease biomarker assays and generating the clinical evidence to drive clinical adoption.
This partnership addresses the global unmet clinical need for blood-based Alzheimer's Disease diagnostics through continued menu expansion on Beckman Coulter's Access Family of Immunoassay Analysers leveraging Fujirebio's assay technology. Initial assay development efforts will focus on the recently introduced DxI 9000 Access Immunoassay Analyser and the widespread installed base of Access Family Immunoassay Analysers.
